These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled clinical trial. Niendorf HP; Haustein J; Louton T; Beck W; Laniado M Invest Radiol; 1991 Nov; 26 Suppl 1():S221-3; discussion S232-5. PubMed ID: 1808134 [No Abstract] [Full Text] [Related]
5. Pruritus and paresthesia after i.v. administration of Gd-DTPA. Chan K; Bosanko CM; Wang AM AJNR Am J Neuroradiol; 1989; 10(5 Suppl):S53. PubMed ID: 2505565 [No Abstract] [Full Text] [Related]
8. Measurement of relative cerebral blood volume changes with visual stimulation by 'double-dose' gadopentetate-dimeglumine-enhanced dynamic magnetic resonance imaging. Frank JA; Mattay VS; Duyn J; Sobering G; Barrios FA; Zigun J; Sexton R; Kwok P; Woo J; Moonen C Invest Radiol; 1994 Jun; 29 Suppl 2():S157-60. PubMed ID: 7928216 [No Abstract] [Full Text] [Related]
9. MR appearance of extravasated gadolinium contrast medium. Carrier DA; Ford JJ; Hayman LA AJNR Am J Neuroradiol; 1993; 14(2):363-4. PubMed ID: 8456712 [TBL] [Abstract][Full Text] [Related]
10. Generalized seizure after i.v. administration of gadopentetate dimeglumine. Harbury OL AJNR Am J Neuroradiol; 1991; 12(4):666. PubMed ID: 1882740 [No Abstract] [Full Text] [Related]
11. Cutaneous nodules, pain, and thrombophlebitis as an adverse reaction to gadolinium contrast media. Murphy KJ; Hansen R; Prince MR AJR Am J Roentgenol; 1997 Jul; 169(1):318-9. PubMed ID: 9207574 [No Abstract] [Full Text] [Related]
12. [Oral contrast media for magnetic resonance tomography of the abdomen. III. Initial patient research with gadolinium-DTPA]. Claussen C; Kornmesser W; Laniado M; Kaminsky S; Hamm B; Felix R Rofo; 1988 Jun; 148(6):683-9. PubMed ID: 2837806 [TBL] [Abstract][Full Text] [Related]
13. Acute deterioration of myasthenia gravis after intravenous administration of gadolinium-DTPA. Nordenbo AM; Somnier FE Lancet; 1992 Nov; 340(8828):1168. PubMed ID: 1359250 [No Abstract] [Full Text] [Related]
14. Can gadolinium be safely given in renal failure? Weissleder R AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405 [No Abstract] [Full Text] [Related]
15. Importance of a previous allergy to an iodinated contrast agent in the administration of gadopentetate dimeglumine. García N; Ramón E; Gonzalez del Valle L; Ruano M; Jiménez E Ann Pharmacother; 1997 Mar; 31(3):374. PubMed ID: 9066954 [No Abstract] [Full Text] [Related]
16. Laryngospasm after administration of gadopentetate dimeglumine. Omohundro JE; Elderbrook MK; Ringer TV J Magn Reson Imaging; 1992; 2(6):729-30. PubMed ID: 1446118 [TBL] [Abstract][Full Text] [Related]
17. Fatal reaction to gadopentetate dimeglumine. Jordan RM; Mintz RD AJR Am J Roentgenol; 1995 Mar; 164(3):743-4. PubMed ID: 7863905 [No Abstract] [Full Text] [Related]
18. [Oral contrast media for the magnetic resonance tomography of the abdomen. A clinical trial of the tolerance for gadolinium-DTPA]. Kaminsky S; Laniado M; Gogoll M; Kornmesser W; Clauss W; Felix R Rofo; 1992 Jan; 156(1):17-23. PubMed ID: 1733470 [TBL] [Abstract][Full Text] [Related]
19. Considerations in the choice of contrast media for MR imaging. Brasch RC; Bennett HF Radiology; 1988 Mar; 166(3):897-9. PubMed ID: 3340795 [No Abstract] [Full Text] [Related]
20. Severe adverse drug reaction to gadobenate dimeglumine. Singer BD; Woodrick RS; Pedicano JB ScientificWorldJournal; 2009 May; 9():363-5. PubMed ID: 19468658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]